Nvidia bets on agentic AI to turbocharge biotech discovery - SiliconANGLE

At the Bio International Convention in San Diego, NVIDIA's Kimberly Powell emphasized the transformative potential of agentic AI in biotechnology, arguing that it will revolutionize the industry much ... Read original →

NVIDIA’s BioNeMo isn’t just a toolkit—it’s a strategic land grab to embed agentic AI into the scientific method itself. By anchoring this shift in CUDA-X and domain-specific libraries, NVIDIA forces upstream EDA and downstream CADD tools to adapt or perish, potentially accelerating demand for sub-3nm and EUV capacity through compute-intensive molecular simulations. Regulatory scrutiny over genomic data flows in the EU and U.S. will inflate compliance costs for cloud-based AI adoption, spurring on-prem HPC deployments. Competitors like Cerebras may double down on wafer-scale inference efficiency, while Anthropic could integrate Claude with robotic labs to bypass NVIDIA’s stack. Within 18 months, biotechs lacking agent orchestration capabilities risk obsolescence; those defining the AI scientist workflow will control the new research paradigm—reshaping not just drug discovery, but who owns scientific authority.